eScholarship
metadata only
PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment
Severe asthma accounts for almost half the cost associated with asthma. Severe asthma is driven by heterogeneous molecular mechanisms. Conventional clinical trial design often lacks the power and efficiency to target subgroups with specific pathobiological mechanisms. Furthermore, the validation and
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study#1139398
- Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma#1162145
- High-Throughput Screening Identifies Small-Molecule Inhibitors of the Tau-LRP1 Interaction#1149577
- The Severe Asthma Research Program III-Boston Clinical Site#841910
- Peripheral Endothelial Function in Asthmatic Patients#1172190
Record · ID 1015677
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive